MAIA - AMEX

MAIA Biotechnology, Inc.

MAIA·AMEX

$1.49

+4.2%

HealthcareBiotechnology

MAIA Biotechnology, Inc., a clinical stage biotechnology company, engages in the discovery, development, and commercialization of therapies targeting cancer, primarily non-small cell lung cancer. Its lead asset, THIO, is an investigational dual mechanism of action drug candidate incorporating telomere targeting and immunogenicity. The company was founded in 2018 and is headquartered in Chicago, Illinois.

Statements Value Model

At a Glance

Live Snapshot

Market Cap$90.59M

EPS-0.7000

P/E Ratio-2.13

Earnings Date08/10/2026

No Revenue Data

MAIA has not reported any revenue values in the available annual periods.

-22.40M

Net Income

-4%

3Y+42.0%

5Y+237.0%

10Y+245.0%

-18.84M

Operating Cash Flow

20%

3Y+56.0%

5Y+922.0%

10Y+1104.0%

MAIA Biotechnology, Inc. Profit Bridge

MAIA · AMEX

Revenue & Cost of Sales

Revenue0.00

Cost of Goods Sold (0.00)

Gross Profit0.00

Operating Expenses

Operating Expenses (24.27M)

Operating Income-24.27M

Other Income & Taxes

Interest Expense (0.00)

Other Income/Expense1.87M

Pretax Income-22.40M

Income Tax (0.00)

Net Income-22.40M

Net Income

-22.40M

Profitability Analysis

MAIA Biotechnology, Inc. Income Statement

MAIA • AMEX

MAIA Biotechnology, Inc. Income Statement	Dec 2025	Dec 2024	Dec 2023	Dec 2022	Dec 2021	Dec 2020	Dec 2019
REVENUE
GROSS PROFIT
OPERATING INCOME
Operating Expenses	(24.3M)	(17M)	(20.2M)	(16.2M)	(7.8M)	(7M)	(6.9M)
Selling, General & Administrative	(9.7B)	(6.9M)	(9.1M)	(6.1M)	(4.3M)	(5.6M)	(5M)
Research & Development	(14.5B)	(10M)	(11.1M)	(8.9M)	(3.5M)	(1.4M)	(1.9M)
Operating Income	-24.3M	-17M	-20.2M	-16.2M	-7.8M	-7M	-6.9M
PRE-TAX INCOME
Interest Expense	(0.0)	(57.0)	(0.0)	(7K)	(827.5K)	(31.5K)	(0.0)
Net Interest Income	314K	318.3K	27.6K	-5.1K	-825.5K	-31.5K	242.0
Other Expenses	-24.2B	(0.0)	(0.0)	(1.1M)	(43.7K)	(0.0)	(0.0)
Total Other Income Expenses Net	1.9M	-6.3M	409.5K	406.9K	-4.8M	16.4K	242.0
Income Before Tax	-22.4M	-23.3M	-19.8M	-15.8M	-12.6M	-7M	-6.9M
NET INCOME
Net Income	-22.4M	-23.3M	-19.8M	-15.8M	-12.5M	-6.6M	-6.5M

SEC Filings

MAIA - Filing history and reports

Filing Type	Filing Date	Period Ending	Fiscal Year	Actions
8-K 8-K 2026 N/A	May 22, 2026	May 21, 2026	2026	View Filing
8-K 8-K 2026 N/A	May 14, 2026	May 14, 2026	2026	View Filing
10-Q 10-Q 2026 Q1 Q1	May 11, 2026	March 31, 2026	2026	View Filing
8-K 8-K 2026 N/A	April 16, 2026	April 16, 2026	2026	View Filing
8-K 8-K 2026 N/A	April 08, 2026	April 08, 2026	2026	View Filing
DEF 14A DEF 14A 2026 N/A	April 07, 2026	May 21, 2026	2026	View Filing
8-K 8-K 2026 N/A	April 02, 2026	March 27, 2026	2026	View Filing
8-K 8-K 2026 N/A	March 31, 2026	March 31, 2026	2026	View Filing
8-K 8-K 2026 N/A	March 27, 2026	March 27, 2026	2026	View Filing
10-K 10-K 2025 FY FY	March 23, 2026	December 31, 2025	2025	View Filing

Showing 1 to 10 of 143 filings

Related Guides

Blog Categories

Continue your MAIA research with focused valuation guides.

Fundamentals

Decode statement quality and operating durability.

Accounting

Interpret line items with cleaner analytical framing.

Forecasting

Translate historical performance into forward scenarios.

Reference

Use practical frameworks for statement-led valuation.

Research Paths

Pick your next lens

Snapshot

Start with context, operating signals, and key market metrics.

Value Model

Stress test fair value across bear, base, and bull assumptions.

Statements

Validate revenue quality, margins, and balance sheet durability.

Earnings Call

Read management commentary and compare it with reported outcomes.

Dividends

Check payout sustainability and long-term distribution behavior.

Analyst Expectations

Review consensus spread and where estimate risk is concentrated.